- Home
- / Vivoryon Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Vivoryon Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€2.4
2024-10-29
Market Capitalization
€64.7 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.8M | (3.6M) | ||||||
| Cost of goods sold | 2.1M | 2.7M | 1.4M | (525.0K) | ||||
| Gross profit | (2.1M) | (2.7M) | 6.0K | 9.4M | 19.0K | (2.6M) | 265.0K | |
| Gross profit margin, % | 87.0% | 71.8% | ||||||
| Operating expense total | 5.5M | 6.9M | 15.9M | 22.0M | 29.0M | 26.1M | 20.8M | 9.0M |
| Depreciation and amortization | 23.0K | 35.0K | 146.0K | 165.0K | 127.0K | 120.0K | 147.0K | 147.0K |
| EBITDA | (7.6M) | (9.6M) | (15.9M) | (12.6M) | (29.0M) | (28.7M) | (20.8M) | (8.8M) |
| EBITDA margin, % | -117.4% | 793.3% | ||||||
| EBIT | (7.6M) | (9.7M) | (16.0M) | (12.8M) | (29.1M) | (28.8M) | (21.0M) | (8.9M) |
| EBIT margin, % | -118.9% | 796.6% | ||||||
| Interest income | 25.0K | 21.0K | 42.0K | 478.0K | 426.0K | 101.0K | ||
| Interest expense | 115.0K | 114.0K | 49.0K | 226.0K | 24.0K | 56.0K | 47.0K | 45.0K |
| Pre tax profit | (7.7M) | (9.7M) | (16.5M) | (12.2M) | (28.4M) | (28.6M) | (20.6M) | (8.9M) |
| Income tax expense | 432.0K | (199.0K) | (234.0K) | |||||
| Net Income | (7.7M) | (9.7M) | (16.5M) | (12.7M) | (28.2M) | (28.3M) | (20.6M) | (8.9M) |